Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nacubactam and Meropenem in cUTI
NCT03174795Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of Nacubactam in complicated urinary tract infection (cUTI), sponsored by Roche. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval, Total Clearance and 6 more. Started Jul 2017; status: completed.
02
Drugs
Nacubactam
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03174795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174795.